H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Theravance Biopharma (TBPH) to $20 from $15 and keeps a Buy rating on the shares following the Q3 report. Net sales of Yupelri reached an all-time high of $71.4M, the analyst tells investors in a research note. The firm upped estimates for 2026 and beyond.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH: